ZURICH, Jan 24 (Reuters) - Europe’s drive to cut drug prices coupled with U.S. healthcare reforms will weigh on global pharmaceutical companies’ growth outlooks for 2011. Investors will look at comments on how the changing landscape on both sides of the Atlantic will hit 2011 revenue, once U.S. group Johnson & Johnson (JNJ.N) kicks off the fourth-quarter earnings season on Tuesday.
